The success of oil-based plastics and the continued growth of production and utilisation can
be attributed to their cost, durability, strength to weight ratio, and eight contributions to the …

Current clinical treatment strategies for the bypassing of small diameter (< 6 mm) blood
vessels in the management of cardiovascular disease frequently fail due to a lack of suitable …

During the resorbable-polymer-boom of the 1970s and 1980s, polycaprolactone (PCL) was
used extensively in the biomaterials field and a number of drug-delivery devices. Its …

Occlusive arterial disease, including coronary heart disease (CHD) and peripheral arterial
disease (PAD), is the main cause of death, with an annual mortality incidence predicted to …

Tissue engineered vascular grafts (TEVGs) are beginning to achieve clinical success and
hold promise as a source of grafting material when donor grafts are unsuitable or …

Biodegradable scaffolds seeded with bone marrow mononuclear cells (BMCs) are the
earliest tissue-engineered vascular grafts (TEVGs) to be used clinically. These TEVGs …

Currently available synthetic grafts have contributed to improved outcomes in cardiovascular
surgery. However, the implementation of these graft materials at small diameters have …

Vascular tissue engineering has significant potential to make a major impact on a wide array
of clinical problems. Continued progress in understanding basic vascular biology will be …

Cardiovascular tissue engineering aims to find solutions for the suboptimal regeneration of
heart valves, arteries and myocardium by creating 'living'tissue replacements outside (in …

Advancements in congenital heart surgery have heightened the importance of durable
biomaterials for adult survivors. Dystrophic calcification poses a significant risk to the long …